Pirfenex Tablet By C. B. Pharma

Each film-coated tablet contains

Pirfenidone IP ............... 200 mg

Colour: Titanium Dioxide IP

Pirfenidone is a pyridine molecule with anti-inflammatory and antifibrotic activities that have been reported both in vitro and in vivo. The mechanism of action of pirfenidone has not been fully established. However, existing data suggest that pirfenidone exerts both antifibrotic and anti-inflammatory properties in a variety of in vitro systems and animal models of pulmonary fibrosis (bleomycin- and transplant-induced fibrosis).

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic and inflammatory pulmonary disease affected by the synthesis and release of pro-inflammatory cytokines including tumour necrosis factor-alpha (TNF-I ) and interleukin-1a beta (IL-1I ) and pirfenidone has been shown to reduce the accumulation of inflammatory cells in response to various stimuli.

Pirfenidone attenuates fibroblast proliferation, production of fibrosis-associated proteins and cytokines, and the increased biosynthesis and accumulation of extracellular matrix in response to cytokine growth factors such as, transforming growth factor-beta (TGF-I ) and platelet-derived growth factor (PDGF).

Ex vivo, pirfenidone inhibited fibroblast proliferation, differentiation and related collagen synthesis and inhibits its degradation. Pirfenidone reduced the production of other mediators of fibrogenesis, such as fibronectin and connective tissue growth factor . Moreover, in a murine macrophage-like cell line , pirfenidone inhibited TNF-alpha synthesis in vitro, whereas it increased the production of IL-10 (with anti-inflammatory activity) in the murine endotoxin shock model in vivo. Pirfenidone has also been shown to reduce the levels of platelet-derived growth factors, A and B in bronchoalveolar lavage in a hamster model of bleomycin- induced lung fibrosis.